Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

被引：1
|
作者：
Wyatt, Nicola [1 ]
Hogarth, Linda [1 ]
Turner, Dianne [2 ]
Patterson, Miranda [2 ]
Jamieson, David [1 ]
Black, Fiona [3 ]
Hutton, Claire [1 ]
Mulvenna, Paula [2 ]
Simmons, Tim [2 ]
Bradshaw, Alexander [2 ]
Kolenda, Claire [4 ]
Parker, Craig [4 ]
Martin-Ruiz, Carmen [4 ]
Greystoke, Alastair [1 ]
机构：
[1] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England
[2] Newcastle Upon Tyne NHS Fdn Trust, Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England
[3] Newcastle Upon Tyne NHS Fdn Trust, Dept Pathol, Newcastle Upon Tyne, Tyne & Wear, England
[4] Newcastle Univ, Newcastle Inst Ageing, Newcastle Upon Tyne, Tyne & Wear, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
frailty; chemotherapy; Biomarkers;
D O I：
10.1016/j.jtho.2016.11.1122
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-070
引用
收藏
页码：S829 / S830
页数：2
相关论文
共 50 条
  • [21] Downregulation of SIRT6 is associated with poor prognosis in patients with non-small cell lung cancer
    Zhu, Bojin
    Yan, Yongjin
    Shao, Boyun
    Tian, Luwen
    Zhou, Weihua
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2018, 46 (04) : 1517 - 1527
  • [22] Wntl overexpression associated with tumor proliferation and a poor prognosis in non-small cell lung cancer patients
    Nakashima, Takashi
    Liu, Dage
    Nakano, Jun
    Ishikawa, Shinya
    Yokomise, Hiroyasu
    Ueno, Masaki
    Kadota, Kyuichi
    Huang, Cheng-Long
    ONCOLOGY REPORTS, 2008, 19 (01) : 203 - 209
  • [23] EXPRESSION OF TRKB AND BDNF IS ASSOCIATED WITH POOR PROGNOSIS IN NON-SMALL CELL LUNG CANCER
    Okamura, Kyoko
    Harada, Taishi
    Wang, Shuo
    Furuyama, Kazuto
    Ijichi, Kayo
    Koga, Takaomi
    Okamoto, Tatsuro
    Takayama, Koichi
    Yano, Tokujiro
    Nakanishi, Yoichi
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S471 - S471
  • [24] Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer
    Okamura, Kyoko
    Harada, Taishi
    Wang, Shuo
    Ijichi, Kayo
    Furuyama, Kazuto
    Koga, Takaomi
    Okamoto, Tatsuro
    Takayama, Koichi
    Yano, Tokujiro
    Nakanishi, Yoichi
    LUNG CANCER, 2012, 78 (01) : 100 - 106
  • [25] LYAR promotes the proliferation of non-small cell lung cancer and is associated with poor prognosis
    Lu, Xiao-Ning
    Ju, Guan-Jun
    Wang, Yu-Xin
    Wang, Yong-Liang
    Wang, Kun
    Chen, Jian-Le
    Cai, Wei
    Zang, Qi-Wei
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2021, 59 (04) : 282 - 290
  • [26] Predictive biomarkers in the treatment of non-small cell lung cancer (NSCLC)
    Niho, Seiji
    CANCER SCIENCE, 2018, 109 : 423 - 423
  • [27] Multiparametric analysis of prognosis in patients with advanced non-small cell lung cancer
    Stefan, Holdenrieder
    von, Pawel J.
    Raith, H.
    Feldmann, K.
    Stenman, U. H.
    Nagel, D.
    Stieber, P.
    TUMOR BIOLOGY, 2006, 27 : 40 - 40
  • [28] SERUM CARCINOEMBRYONIC ANTIGEN (CEA) LEVELS ARE ASSOCIATED WITH WORSE PROGNOSIS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Cedres, S.
    Nunez, I.
    Longo, M.
    Martinez, P. N.
    Rodriguez Checa, E.
    Cazorla, M.
    Felip, E.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S88 - S88
  • [29] Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC)
    Monnet, I
    Brienza, S
    Hugret, F
    Voisin, S
    Gastiaburu, J
    Saltiel, JC
    Soulié, P
    Armand, JP
    Cvitkovic, E
    de Cremoux, H
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (07) : 1124 - 1127
  • [30] Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients
    Franciosi, V
    Barbieri, R
    Aitini, E
    Vasini, G
    Cacciani, GC
    Capra, R
    Camisa, R
    Cascinu, S
    LUNG CANCER, 2003, 41 (01) : 101 - 106
12345